leisure time -WSS

leisure time

author：fashion 2025-09-27 09:47:22 - browse：94974

A screen at the New York Stock Exchange last November. Michael M. Santiago/Getty Images

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline.

The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed. (Pfizer’s current best-seller in oncology, Ibrance for breast cancer, is a small molecule pill.) It said the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030.

That matters because small molecules are more vulnerable to generic competition and the Medicare price negotiation introduced by the IRA. Suneet Varma, the commercial president of Pfizer’s oncology unit, said “this planned shift to biologics is expected to support the accelerated growth in both the top and bottom line,” referring to the revenue and profit lines of a balance sheet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The pink breast cancer awareness ribbon needs a redesign

entertainment

hotspot

WSS

Cassava reveals details — and problems — with Alzheimer's study

STAT Readout Newsletter: Today's biggest biotech updates

FDA struggles to regulate food additives, sometimes for decades

The EU Joint Clinical Assessment needs to live up to its promise

CEOs share strategies for surviving biotech slump

First Opinion Podcast: Long Covid needs a new approach

explore

leisure time

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Senate panel to vote on hospitals, PBMs, prisoner care

Tori Bowie and the unacceptable rates of Black maternal death

How climate

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA warns J&J's Abiomed: We will regulate your software

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Readout Newsletter: Today's biggest biotech updates

Activists slam private health insurers over coverage restrictions

The FDA weighs the risks of candy

hotspot

Diversifying clinical trials isn't enough to close racial gaps: study

FDA struggles to regulate food additives, sometimes for decades

Diversifying clinical trials isn't enough to close racial gaps: study

Why health workers in Gaza are injured or die at high rates

How climate

Lawmakers consider Medicare pay reforms for doctors

leisure time

entertainment

hotspot

leisure time